Automation, and its big brother AI, have been hot topics in Pharmacovigilance for several years now, with the promise that between them, they will do almost anything and everything to reduce manual processes. So, if that’s the case, there should be almost universal adoption within the industry.
For Dr. John Price, his experience as a consultant for clients around the world is that there has in fact been very little uptake of these next-generation tech solutions for case intake, considering the improvements to data quality and efficiency that they should bring.
Why is that? What are the barriers that might prevent or delay adoption? As an advisory Board member for Consultant Services provider Arriello, who also provide an automated case-intake solution, finding out more about this has been of interest to both sides. So, in June 2020, Arriello commissioned a US/UK survey of 200 PV professionals to ask some key questions around the topic of case intake automation and adjacent PV activities to get an up-to-date snapshot of current sentiment.
Dr. John Price, MB ChB, PhD, BSc, Pharmacovigilance Consultant, Arriello Advisory Board member
Dr. John Price is an executive physician with deep experience gained from over 25 years working across the breadth of regulatory affairs and pharmacovigilance worldwide. He has created and led high-functioning global departments for pharmacovigilance, regulatory and clinical operations, medical writing and drug development, and held senior roles in the UK Medicines Control Agency (now MHRA), Pfizer, J&J, Alexion Pharmaceuticals, and academia.
Dr. Price has successfully operated within the ever-changing complexities of international regulatory affairs, participating directly in pharmacovigilance inspections in the US and Europe, building globally compliant drug safety systems, delivering risk management plans to meet regulatory expectations worldwide, and defending labeling and REMS at regulatory agency advisory committee meetings.
A consistent driving force for Dr. Price is the implementation of efficient and effective pharmacovigilance systems that enable companies to return budget for the development of future medicines.Message Presenter
Who Should Attend?
- Heads/Directors of Drug Safety, Pharmacovigilance, Product Safety
- Heads/Directors of Procurement
- Heads/Directors of Safety Data/, CRS Processing, SUSAR Processing, Collection of safety data
- Heads/Directors of Innovation/Automation/AI/Early Adoption
- Heads/Directors of Commercial/Business Development
What You Will Learn
- A snapshot of case intake and PV automation adoption in the US and UK
- An exploration of where the adoption of case intake automation sits amongst adjacent safety activities
- The 3 main barriers to adoption from our survey
- That the benefits of adopting automation that aren’t widely appreciated
Arriello has been a leading provider of risk management and compliance services to the life sciences sector since 2008. These include market consultancy, global regulatory affairs strategy and implementation, full and local pharmacovigilance solutions, clinical drug safety, and quality and compliance auditing and systems. Our brief is simple; to make the process from development to market faster, better and smarter.
Headquartered in Ireland, with European operations in Central Europe, our technical team has a combined experience of over 130 years working across the EU, US, LATAM, MENA, CIS, APAC regions and South Africa. We currently operate in 143 countries with the ability to expand this as required.
With our in-house expertise, vendor network, ISO 9001 certification, years of experience and satisfied clients, including global Originators, Biotech’s, Generics and CRO’s, you can be confident in our ability to deliver as a trusted partner.